<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545595</url>
  </required_header>
  <id_info>
    <org_study_id>OBRITI</org_study_id>
    <nct_id>NCT02545595</nct_id>
  </id_info>
  <brief_title>Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <brief_summary>
    <textblock>
      This randomized double blind clinical trial focuses on patients with Body Masse Index ≥ 40
      kg/m2, undergoing scheduled surgery. Neuromuscular transmission monitoring at the adductor is
      performed using. Anaesthesia is induced with anaesthesic and maintained with curare. At the
      end of the procedure, patients with profound neuromuscular blockade receive either 1 mg/kg, 2
      mg/kg or 4 mg/kg Sugammadex based on ideal body weight. A complete reversal failure is
      defined by a Train Of Four ratio &lt; 0.9 within 10 min after administration of Sugammadex or if
      recurarization occurs within 15 min after complete reversal success.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>determine a profound neuromuscular blockade reversal on ideal body weight</measure>
    <time_frame>30 minutes</time_frame>
    <description>A complete reversal failure is defined by a Train Of Four ratio &lt; 0.9 within 10 min after administration of Sugammadex or if recurarization occurs within 15 min after complete reversal success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare dosages based on ideal body weight to real body weight</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Sugammadex 1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 1 mg/kg</intervention_name>
    <arm_group_label>Sugammadex 1mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <arm_group_label>Sugammadex 2mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <arm_group_label>Sugammadex 4mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General anaesthesia

          -  Neuromuscular blockade induce by rocuronium

          -  Body Masse Indice ≥ 40 kg/m2

          -  informed consent

        Exclusion Criteria:

          -  Contraindication to rocuronium or sugammadex

          -  Pregnant women

          -  Severe renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>General anaesthesia</keyword>
  <keyword>Curarization with rocuronium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

